Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 209-143-5 | CAS number: 556-88-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1988
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Objective of study:
- distribution
- metabolism
- toxicokinetics
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 417 (Toxicokinetics)
- GLP compliance:
- not specified
- Radiolabelling:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Bantin-Kingman (Fremont, CA)
- Weight at study initiation: 150-200g
- Housing: individually in metabolism cages (Nalgene) - AALAS-accredited facilities
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 14 days
- Other: Animals were fasted prior to dosing - Route of administration:
- other: intravenous and orally by intubation
- Vehicle:
- other: physiol. saline or DMSO + 1 % gum tragacanth
- Details on exposure:
- tissue distribution & blood kinetics:
group1: 20 mg/kg intravenously via tail vein with 5-10 µCi of radiolabel NiGu in 0,9% NaCl
group2: 20 mg/kg gavage with 7-11 µCi of radiolabel NiGu dissolved in DMSO & suspended in 1% gum tragacanth
group3: 200 mg/kg gavage with 5-10 µCi of radiolabel NiGu dissolved in DMSO & suspended in 1% gum tragacanth - Duration and frequency of treatment / exposure:
- one-time treatment /exposure
- Dose / conc.:
- 20 mg/kg bw/day
- Remarks:
- i.v.
- Dose / conc.:
- 20 mg/kg bw/day
- Remarks:
- gavage
- Dose / conc.:
- 200 mg/kg bw/day
- Remarks:
- gavage
- No. of animals per sex per dose / concentration:
- group 1: 6 male, 6 female
group 2: 6 male, 6 female
group 3: 6 male, 6 female - Control animals:
- no
- Details on dosing and sampling:
- PHARMACOKINETIC STUDY (Absorption, distribution, excretion)
- Tissues and body fluids sampled: urine, feces, blood, tissues, expired CO2
- Time and frequency of sampling:
- blood (gavage): 10, 20, 30, 40, 50, 60, 75, 90, 120 min; 3, 4, 6, 8, 12, 24 h;
- blood (i.v.): 5, 15, 30, 45, 60, 75, 90, 120 min; 3, 4, 5, 6, 7, 8, 24 h;
- urine samples: 4, 8, 24, 32, and 48 hr
- fecal samples: 24 and 48 hr
Sampling:
urin: 25 - 1000 µl aliquots; liquid scintillation counting (Packard Tri-Carb 4530 or 460-CD or 3390AAA)
feces: lyophilized and crushed; aliquots combusted prior to liquid scintillation counting
CO2: collected by bulbing through absorption towers; aliquots of absorbant were measured by liquid scintillation counting - Statistics:
- Two-way analysis of variance was performed to test for differences in excretion and distribution of radiolabel by the various dose groups at the indicated time points. The Newman-Keuls method of multiple comparisons was then performed to compare excretion of radiolabel by dose group and/or sex. All tests were done at p=0.05 level of significance. Data from blood kinetics experiments were analyzed by non-linear regression analysis to give values for t1/2alpha/2beta, AUC, VDss, tmax, and Cmax.
- Preliminary studies:
- data not shown: no radiolabel present in the expired air
- Details on absorption:
- The absorption of orally dosed (group B) versus i.v. dosed (group A) is 100 %; the route of administration does not appear to influence the absorption of radiolabel.
- Details on distribution in tissues:
- The tissue distribution of [14C]-nitroguanidine is shown in Table 2. After 48 h there was no significant radioactivity (0,02 %) remaining in any organ.
The distribution 1 hour after administration of 20 mg/kg (oral) is shown in Table 3 in the field "Overall remarks and attachments". A large amount of radiolabel is found in the GI tract (5.3 %), as expected with an oral dose, followed by kidney (1.3 %) and liver (1 %). - Details on excretion:
- The administered radioactivity was rapidly excreted in the urine by animals in all dose groups. 40-50% was excreted after 4 h postdose. Approx. 95% of administerd radiolabel was recovered in the urine after 48h; low amount of radiolabel were detected in the feces (likely to be inflated due to urine contamination of feces in the metabolic cages);
The cumulative recovery of radioactivity in the urine is shown in table 1 in the field Overall remarks and attachments.
The distribution and excretion of radioactivity 48 hours after administration of [14C] nitroguanidine is shown in table 2. - Key result
- Test no.:
- #1
- Toxicokinetic parameters:
- half-life 1st: t1/2 α-phase (h): group 1: 0.08 +- 0.01; group 2: 0.21 +- 0.24; group 3: 0.82 +- 0.67
- Key result
- Test no.:
- #2
- Toxicokinetic parameters:
- half-life 2nd: t1/2 β-phase (h): group 1: 1.78 +- 0.14; group 2: 2.60 +- 0.10; group 3: 2.94 +- 1.07
- Key result
- Test no.:
- #3
- Toxicokinetic parameters:
- AUC: AUC (µg/ml/hr): group 1: 79.98 +- 10.05; group 2: 92.64 +- 26.80; group 3: 969.07 +- 149.92
- Key result
- Test no.:
- #4
- Toxicokinetic parameters:
- other: VDss(1/kg): group 1: 0.66 +- 0.12; group 2: 0.87 +- 0.20; group 3: 0.85 +- 0.19
- Key result
- Test no.:
- #5
- Toxicokinetic parameters:
- Tmax: t max(h): group 1: not applicable; group 2: 0.69 +- 0.62; group 3: 1.77 +- 0.86
- Key result
- Test no.:
- #6
- Toxicokinetic parameters:
- Cmax: Cmax(µg/ml): group 1: not applicable; group 2: 19.93 +- 2.01; group 3: 149.44 +- 22.96
- Metabolites identified:
- no
- Details on metabolites:
- Substance is not metabolized and is excreted unchanged as nitroguanidine. Under aerobic conditions nitroguanidine does not undergo metabolism in the rat.
Previous studies showed that :
- Nitroguanidine is reduced to nitrosoguanidine by anaerobic sludge microorganisms. - Conclusions:
- There was no significant radioactivity remaining in any of the major organs of the treated animals. No sex differences in groups were seen in the excretion of the radiolabel after 48 hours. The route of administration does not appear to influence the absorption of radiolabel. No dose dependency of absorption between oral doses of 20 and 200 mg/kg is indicated.
Nitroguanidine is rapidly and completely absorbed in all dose groups. Nitroguanidine is well distributed to the tissues of all animals regardless of the route of administration. Nitroguanidine is rapidly distributed in the blood to the major organs. - Executive summary:
Results from initial experiments showed no radiolabel to be present in the expired air of animals treated with [14C]nitroguanidine. Approximately 95 % of the administered radiolabel was recovered in the urine of the animals in all dose groups after 48 hours. The amount of radioactivity in the feces was low and it is likely that these values are inflated due to urine contamination of the feces in the metabolic cages. At 48 hours after dosing, the animals were removed for analysis. There was no significant radioactivity remaining in any of the major organs of the treated animals.
The administered radioactivity was rapidly excreted in the urine by animals in all dose groups. Between 40 and 50 % of the radiolabel had been excreted in the urine 4 hours postdose and nearly all the administrated radiolabel was found in the urine after 24 hours.
No sex differences in groups were seen in the excretion of the radiolabel after 48 hours.
The absorption of radiolabel by orally dosed group B versus i.v. dosed group A is 100 %; the route of administration does not appear to influence the absorption of radiolabel.
The GI tract absorption of radiolabel by animals in group 2 and group 3 is essentially complete, indicating no dose dependency of absorption between oral doses of 20 and 200 mg/kg.
The results indicate that nitroguanidine is well distributed to the tissues of all animals regardless of the route of administration or dose regiment and that nitroguanidine is rapidly distributed in the blood to the major organs.
Reference
Results from the reverse-phase HPLC analysis of a representative urine sample indicate the presence of one major radioactive component in the urine, which has an elution volume of 3.7 ml. This elution volume corresponds exactly (99%) to that of nitroguanidine standard as evidenced by uv detection.
Description of key information
Short description of key information on bioaccumulation potential result:
A toxicokinetic study in rat according OECD 417 was conducted to assess absorption,
distribution, elimination and metabolism of Nitroguanidine.
Nitroguanidine is rapidly distributed and rapidly excreted. 40 - 50 % of the substance is excreted in the urine 4 hours postdose
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
Based on an OECD 417 Guideline study in rats Nitroguanidin is considered to be well absorbed regardless of the route of administration or dose regime. Nitroguanidine is rapidly distributed and rapidly excreted. 40 - 50 % of the substance is excreted in the urine 4 hours postdose and nearly all the administered radiolabel was found in the urine after 24 hours. No metabolites were identified.
Discussion on bioaccumulation potential result:
Nitroguanidine is rapidly and completely absorbed in all dose groups. The bioavailability of NG in orally dosed groups is 100% as compared to the i.v. dosed group when calculated using either urinary or blood level data. Initial experiments showed no radiolabel to be present in the expired air. Nitroguanidine is well distributed to the tissues of all animals regardless of the sex, route of administration or dose regime. Nitroguanidine is rapidly excreted in the urine by animals in all dose groups. Between 40 and 50 % of the radiolabel is excreted in the urine 4 hours postdose and nearly all the administrated radiolabel was found in the urine after 24 hours. After 48 h the excretion is considered quantitative. Nitroguanidine is not metabolized but excreted solely in its unchanged form.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.